erlotinib hydrochloride has been researched along with pf 3084014 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (pf 3084014) | Trials (pf 3084014) | Recent Studies (post-2010) (pf 3084014) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 46 | 7 | 43 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | pf 3084014 (IC50) |
|---|---|---|---|
| Presenilin-1 | Homo sapiens (human) | 0.0068 | |
| Presenilin-2 | Homo sapiens (human) | 0.0068 | |
| Gamma-secretase subunit APH-1B | Homo sapiens (human) | 0.0068 | |
| Nicastrin | Homo sapiens (human) | 0.0068 | |
| Gamma-secretase subunit APH-1A | Homo sapiens (human) | 0.0068 | |
| Gamma-secretase subunit PEN-2 | Homo sapiens (human) | 0.0068 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, X; Dong, Y; Gu, W; Song, X; Wang, Z; Wu, Y; Zhang, W; Zheng, Y; Zhong, Y | 1 |
1 other study(ies) available for erlotinib hydrochloride and pf 3084014
| Article | Year |
|---|---|
Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Invasiveness; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Valine; Xenograft Model Antitumor Assays | 2018 |